Last reviewed · How we verify
Active compared Vaccine
This is a recombinant protein vaccine designed to stimulate immune responses against a specific pathogen or disease target.
At a glance
| Generic name | Active compared Vaccine |
|---|---|
| Sponsor | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
As a vaccine candidate in Phase 3 development by Anhui Zhifei Longcom, it likely uses recombinant protein technology to present antigenic epitopes to the immune system, triggering both humoral and cellular immune responses. The exact target antigen and mechanism require confirmation from clinical trial data, as the specific indication is not provided.
Approved indications
Common side effects
- Injection site reactions
- Fever
- Myalgia
Key clinical trials
- A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls/Women Aged 15 to 20 Years in Zambia (PHASE4)
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population (PHASE3)
- To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV (PHASE1)
- High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients (PHASE2)
- Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months (PHASE3)
- Confirmatory Study of BK1310 in Healthy Infants (PHASE3)
- High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Active compared Vaccine CI brief — competitive landscape report
- Active compared Vaccine updates RSS · CI watch RSS
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. portfolio CI